Gemtuzumab ozogamicin in acute myeloid leukemia revisited

F Thol, RF Schlenk - Expert opinion on biological therapy, 2014 - Taylor & Francis
Introduction: Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …
被引用次数：55 相关文章

Gemtuzumab ozogamicin in acute myeloid leukemia revisited

F Thol, RF Schlenk - Expert opinion on biological therapy, 2014 - pubmed.ncbi.nlm.nih.gov
Introduction Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …

[引用][C] Gemtuzumab ozogamicin in acute myeloid leukemia revisited

F Thol, RF Schlenk - 2014 - oparu.uni-ulm.de
acute myeloid leukemia, CD33, cytogenetic risk group, gemtuzumab ozogamicin,
EXTRAMEDULLARY AML RELAPSE, OLDER PATIENTS, INDUCTION CHEMOTHERAPY …

Gemtuzumab ozogamicin in acute myeloid leukemia revisited.

F Thol, RF Schlenk - Expert Opinion on Biological Therapy, 2014 - europepmc.org
Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a recombinant
humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was approved by …